Molecular Partners AG (XSWX:MOLN) EBIT per Share : CHF-1.78 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG EBIT per Share?

Molecular Partners AG's EBIT per Share for the three months ended in Mar. 2024 was CHF-0.34. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was CHF-1.78.

During the past 3 years, the average EBIT per Share Growth Rate was 7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Molecular Partners AG's EBIT per Share or its related term are showing as below:

XSWX:MOLN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -149.3 Med: -21.5 Max: 7.2
Current: 7.2

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Molecular Partners AG was 7.20% per year. The lowest was -149.30% per year. And the median was -21.50% per year.

XSWX:MOLN's 3-Year EBIT Growth Rate is ranked better than
54.87% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs XSWX:MOLN: 7.20

Molecular Partners AG's EBIT for the three months ended in Mar. 2024 was CHF-11.32 Mil.

Molecular Partners AG EBIT per Share Historical Data

The historical data trend for Molecular Partners AG's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG EBIT per Share Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.69

-2.50

-2.04

3.56

-1.89

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.45	-0.49	-0.35	-0.60	-0.34

Molecular Partners AG EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Molecular Partners AG's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-61.95	/	32.771
=	-1.89

Molecular Partners AG's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.318	/	32.869
=	-0.34

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.78

Molecular Partners AG (XSWX:MOLN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Molecular Partners AG EBIT per Share Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.